TransCode Says Phase 1a Cancer Trial Meets Safety Goal, Advances Drug to Phase 2a

MT Newswires Live

Jun 03

TransCode Therapeutics (RNAZ) said Wednesday that its Phase 1a dose-escalation trial of cancer therapy TTX-MC138 met its primary safety endpoint, with no dose-limiting toxicities observed across 16 patients treated.

The company said 9 of 14 evaluable patients, or 64%, achieved stable disease lasting at least six months. Three patients remain on treatment, with one receiving therapy for 21 cycles, it added.

TTX-MC138, an investigational inhibitor of microRNA-10b, is being developed to target metastatic cancer. TransCode said it selected 4.8 mg/kg as the recommended Phase 2a dose and plans to evaluate the therapy in patients with circulating tumor DNA-positive colorectal cancer following curative-intent treatment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2640590262"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2640590262\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2640590262?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 21:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640590262","market":"nz","top_or_hot":-1,"title":"TransCode Says Phase 1a Cancer Trial Meets Safety Goal, Advances Drug to Phase 2a","media":"MT Newswires Live","content":"<html><body><p> TransCode <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (RNAZ) said Wednesday that its Phase 1a dose-escalation trial of cancer therapy TTX-MC138 met its primary safety endpoint, with no dose-limiting toxicities observed across 16 patients treated.</p><p>The company said 9 of 14 evaluable patients, or 64%, achieved stable disease lasting at least six months. Three patients remain on treatment, with one receiving therapy for 21 cycles, it added.</p><p>TTX-MC138, an investigational inhibitor of microRNA-10b, is being developed to target metastatic cancer. TransCode said it selected 4.8 mg/kg as the recommended Phase 2a dose and plans to evaluate the therapy in patients with circulating tumor DNA-positive colorectal cancer following curative-intent treatment.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TransCode Says Phase 1a Cancer Trial Meets Safety Goal, Advances Drug to Phase 2a</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTransCode Says Phase 1a Cancer Trial Meets Safety Goal, Advances Drug to Phase 2a\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-03 21:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> TransCode <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (RNAZ) said Wednesday that its Phase 1a dose-escalation trial of cancer therapy TTX-MC138 met its primary safety endpoint, with no dose-limiting toxicities observed across 16 patients treated.</p><p>The company said 9 of 14 evaluable patients, or 64%, achieved stable disease lasting at least six months. Three patients remain on treatment, with one receiving therapy for 21 cycles, it added.</p><p>TTX-MC138, an investigational inhibitor of microRNA-10b, is being developed to target metastatic cancer. TransCode said it selected 4.8 mg/kg as the recommended Phase 2a dose and plans to evaluate the therapy in patients with circulating tumor DNA-positive colorectal cancer following curative-intent treatment.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2640590262","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640590262","pubTimestamp":1780491877,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"TransCode Therapeutics  said Wednesday that its Phase 1a dose-escalation trial of cancer therapy TTX-MC138 met its primary safety endpoint, with no dose-limiting toxicities observed across 16 patients treated.The company said 9 of 14 evaluable patients, or 64%, achieved stable disease lasting at least six months. Three patients remain on treatment, with one receiving therapy for 21 cycles, it added.TTX-MC138, an investigational inhibitor of microRNA-10b, is being developed to target metastatic cancer. TransCode said it selected 4.8 mg/kg as the recommended Phase 2a dose and plans to evaluate the therapy in patients with circulating tumor DNA-positive colorectal cancer following curative-intent treatment.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4139":"生物科技","RNAZ":"TransCode Therapeutics  Inc."},"translate_title":"TransCode表示1a期癌症试验符合安全目标，将药物推进至2a期","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNAZ":1},"content_text":"TransCode Therapeutics (RNAZ) said Wednesday that its Phase 1a dose-escalation trial of cancer therapy TTX-MC138 met its primary safety endpoint, with no dose-limiting toxicities observed across 16 patients treated.The company said 9 of 14 evaluable patients, or 64%, achieved stable disease lasting at least six months. Three patients remain on treatment, with one receiving therapy for 21 cycles, it added.TTX-MC138, an investigational inhibitor of microRNA-10b, is being developed to target metastatic cancer. TransCode said it selected 4.8 mg/kg as the recommended Phase 2a dose and plans to evaluate the therapy in patients with circulating tumor DNA-positive colorectal cancer following curative-intent treatment.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}